Study To Assess the Pharmacokinetics of AZD1656 During Coadministration With Simvastatin

• Status: Completed
• Trial end date: 2010-08-01
• Target enrollment: 0
• Participant gender: All

Summary

To assess the pharmacokinetics of AZD1656 during coadministration with Simvastatin.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AstraZeneca
• Treatments: Simvastatin

Criteria

Inclusion Criteria:

• Patients with a clinical diagnosis of T2DM for at least 1 year, treated with any metformin or metformin with one other oral anti-diabetic drug (OAD)

• Body mass index between greater than or equal to 19 and less than or equal to 42 kg/m2

• HbA1c greater than 6.5% at enrollment

Exclusion Criteria:

• Clinically significant illness or clinically relevant trauma, as judged by the Investigator, within 2 weeks before the first administration of the IP

• Significant cardiovascular event within the last 6 months prior to enrollment (eg, myocardial infarction/acute coronary syndrome, revascularisation procedure, stroke or transient ischaemic attack) or heart failure New York Heart Association (NYHA) class III-IV